Replimune Group Inc. (REPL) experienced a surprising 5.19% plummet in Tuesday's pre-market trading, despite receiving several positive analyst upgrades. This contradictory movement has left investors puzzled as positive analyst sentiment typically drives stock prices higher.

The day saw multiple financial institutions revising their outlook on Replimune Group. Piper Sandler upgraded the stock to Overweight from Neutral and significantly raised its price target to $13 from $8. Similarly, JP Morgan upgraded REPL to Neutral from Underweight. Jefferies also showed confidence by raising its price target to $13 from $8. These upgrades would normally signal bullish sentiment and drive the stock price upward.

However, the pre-market plunge suggests that investors may be focusing on less optimistic views. Notably, Barclays maintained a Hold rating on Replimune Group with a significantly lower price target of $3.00. This conservative outlook from Barclays could be weighing heavily on investor sentiment, potentially explaining the stock's downward movement despite the other upgrades. The stark contrast between Barclays' low target and the higher targets from other analysts highlights the uncertainty surrounding Replimune Group's future prospects, leading to increased volatility in its stock price.